Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00371150 · ClinicalTrials.gov registry record · Phase 4

Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

A Phase 4 study of Hepatitis B Infection, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 4
Development phase
131
Enrollment target
20
Study locations

NCT00371150 is a Phase 4 study of Hepatitis B Infection that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 131 participants. The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00371150, a Phase 4 study of Hepatitis B Infection, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 4
Development phase
131 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.

Conditions Studied

Interventions

  • DRUG Entecavir

Study Locations (20)

Florida

  • University Of Miami - Miami
  • Empire International Research - Miami

Massachusetts

  • Brigham And Women'S Hospital - Boston
  • L L C Bda The Research Institute - Springfield

New York

  • Va New York Harbor Healthcare System - New York
  • Westchester Digestive Disease Group, Llp - Yonkers

São Paulo

  • Local Institution - Campinas
  • Local Institution - Sao Paulo - Sp

Alabama

  • Alabama Liver & Digestive Specialists (Alds) - Montgomery

Arizona

  • University Of Arizona - Tucson

District of Columbia

  • George Washington University Medical Center - Washington D.C.

Illinois

  • University Of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2006-11
Est. Completion 2011-03
Phase Phase 4

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT00371150

The ClinicalTrials.gov registry entry for NCT00371150 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis B Infection appearing as the primary indexed condition, and to 1 intervention - of which Entecavir is the first listed.

NCT00371150 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT00371150 about?

NCT00371150 is a clinical study titled "Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection". The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.

What is the current status of trial NCT00371150?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 131 participants. The study started on 2006-11. Estimated completion is 2011-03.

What conditions does trial NCT00371150 study?

This clinical trial studies the following conditions: Hepatitis B Infection.

What interventions are being tested in trial NCT00371150?

The interventions under investigation include: Entecavir (DRUG).

Who is sponsoring clinical trial NCT00371150?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00371150 being conducted?

This trial has 20 study locations across Alabama, Arizona, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hepatitis B Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.